Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
Medscape7d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
Medscape25d
Early Intervention Central to Treating Muscle Mass Loss in Patients Losing Weight With GLP-1 Meds
With glucagon-like peptide 1 (GLP-1) agonists now close to inducing weight loss at levels only seen before through surgical intervention, obesity specialists say patients on these drugs are ...
Peoples Democracy8d
GLP-1 drugs: Revolutionising Health, as Long as You’re Rich Enough
GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...
BBC2y
Protein structure and variety
The sequence of amino acids in the chain determines ... The shape of a protein determines what it can interact with, just like the shape of a key determines which locks it can operate.
standardmedia.co.ke6mon
A full analysis of Retatrutide and Tirzepatide Peptides
Retatrutide is a synthetic peptide, which research indicates functions as a triple agonist for type 2 diabetes and weight loss. Peptides, small chains of amino acids, have been hypothesized to ...